Tajikistan
Malaria risk—predominantly due to P. vivax—exists from June through October, particularly in southern border areas (Khatlon Region), and in some central (Dushanbe), western (Gorno-Badakhshan), and northern (Leninabad Region) areas. Chloroquine-resistant P. falciparum suspected in some areas.

Tanzania, United Republic of
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country below 1800 m. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.

Thailand
Malaria risk exists throughout the year in rural, especially forested and hilly, areas of the whole country, mainly towards the international borders. There is no risk in cities and the main tourist resorts (e.g. Bangkok, Chiangmai, Pattaya, Phuket, Samui). P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. Resistance to mefloquine and to quinine reported from areas near the borders with Cambodia and Myanmar.

Timor-Leste
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole territory. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.

Togo
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Chloroquine-resistant P. falciparum reported.

Turkey
Malaria risk—exclusively due to P. vivax—exists from May to October mainly in the south-eastern part of the country, and in Amikova and Çukurova Plain. There is no malaria risk in the main tourist areas in the west and south-west of the country.

Turkmenistan
Malaria risk—exclusively due to P. vivax—exists from June to October in some villages located in the south-eastern part of the country, mainly in Mary district.

Uganda
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country including the main towns of Fort Portal, Jinja, Kampala, Mbale and parts of Kigezi. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.

Uzbekistan
Sporadic autochthonous cases of P. vivax malaria are reported from Surkhanda-rinskaya Region (Uzunskiy, Sariassiskiy and Shurchinskiy districts).

Vanuatu
Low to moderate malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. P. vivax resistant to chloroquine reported.

Venezuela
Malaria risk due to P. vivax exists throughout the year in some rural areas of Apure, Amazonas, Barinas, Bolívar, Sucre and Táchira states. Risk of P. falciparum malaria is restricted to municipalities in jungle areas of Amazonas (Atabapo), Bolívar (Cedeño, Gran Sabana, Raul Leoni, Sifontes and Sucre) and Delta Amacuro (Antonia Diaz, Casacoima and Pedernales). Chloroquine-resistant P. falciparum confirmed in the interior of Amazonas state.

Viet Nam
Malaria risk exists in the whole country, excluding urban centres, the Red River delta, and the coastal plains north of Nha Trang. High-risk areas are the two southernmost provinces of the country, Ca Mau and Bac Lieu, and the highland areas below 1500 m south of 18°N. Most cases are caused by P. falciparum. Resistance to chloroquine and sulfadoxine-pyrimethamine reported.

Yemen
Malaria risk—predominantly due to P. falciparum—exists throughout the year, but mainly from September through February, in the whole country below 2000 m. There is no risk in Sana'a city. Resistance to chloroquine reported.

Republic of the Zambia
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.

Zimbabwe
Malaria risk—predominantly due to P. falciparum—exists from November through June in areas below 1200 m and throughout the year in the Zambezi valley. In Harare and Bulawayo, the risk is negligible. Resistance to chloroquine reported.

A - B | C | D - G | H - L | M - O | P - S | T - Z | Return to the country list

World Health Organization. International Travel and Health 2003. Geneva, Switzerland.